Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers

Matthew E Growdon; Chana A Sacks; Aaron S Kesselheim; Jerry Avorn

doi:10.1001/jamainternmed.2019.3107

Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers

JAMA Intern Med. 2019 Dec 1;179(12):1712-1714. doi: 10.1001/jamainternmed.2019.3107.

Authors

Matthew E Growdon^{1

2}, Chana A Sacks^{1

3}, Aaron S Kesselheim¹, Jerry Avorn¹

Affiliations

¹ Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Harvard Medical School Multi-Campus Geriatric Fellowship, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston.

Abstract

This economic evaluation study estimates the potential Medicare savings from generic substitution and therapeutic interchange of brand-name hypertension medications.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / economics
Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / economics
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / economics
Antihypertensive Agents / therapeutic use*
Cost Savings
Drug Substitution / economics*
Drugs, Generic / economics
Drugs, Generic / therapeutic use*
Humans
Hypertension / drug therapy*
Medicare
United States

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Drugs, Generic